Cipla share price today

Cipla Ltd's share price was ₹1,402.00 at the close on 4 November 2026. It has been falling for 3 weeks. That is 0.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,192 and ₹1,532, and at that close it sat 62% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Cipla Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 3 weeks in a row.

Over the last 11 years the share price moved +162% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) raised their stake for 8 quarters in a row, profit down on a year earlier for 4 quarters in a row and operating margin down 6 points on a year earlier.

1. Indian funds and insurers (DIIs) raised their stake for 8 quarters in a row

   From 24% to 34.6% of the company by the September 2026 quarter.

2. Profit down on a year earlier for 4 quarters in a row

   In the September 2026 quarter profit was ₹852 crore, -37% on a year earlier.

   Why: Profit fell because a key US medicine resupply is not coming back this year. That takes away a way for the US business to recover soon.

   Next results: check for a clear FDA update on Lanreotide and whether it comes back.

   From the earnings call on 27 Oct 2026.

3. Operating margin down 6 points on a year earlier

   19% in the September 2026 quarter, from 25%.

   Why: Margin fell because the company spent more on planned launches and getting factories ready.

   Next results: check whether sales from the North American business help the margin recover.

   From the earnings call on 27 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Cipla reported revenue of ₹7,404 crore, down 2.4% from ₹7,589 crore a year earlier, and a profit of ₹852 crore, down 37.0% from ₹1,353 crore.

Cipla results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Cipla's management discussed these results on a call held on 27 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Cipla closed at ₹1,402.00 on 4 November 2026, down 6.9% from ₹1,505.70 a year earlier (7 November 2025) and up 53.9% over five years. Its highest weekly close since March 2016 was ₹1,672.50 on 27 September 2024.

Cipla share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Cipla closed at ₹1,402.00, up 1.7% on the week and up 4.3% on the month. 27 Oct 2026: Cipla held its results call for July to September 2026. Management guided: FY27 US exit run rate of $1 billion annualized, excluding Lanreotide, which is not expected to return this fiscal year.

Earlier

• Results for July to September 2026: Revenue down 2.4% and profit down 37.0% on a year earlier.
• 5 Jun 2026: ex-date for a dividend of ₹13 a share.

Cipla paid ₹13 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.93% at the ₹1,402.00 close on 4 November 2026. The last was a dividend of ₹13 a share, ex-date 5 June 2026.

Cipla dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Cipla Ltd paid out 27% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 27 October 2026, Cipla's management guided: FY27 US exit run rate of $1 billion annualized, excluding Lanreotide, which is not expected to return this fiscal year.

“All of these are complex assets. We do not have plain-vanilla generics in the pipeline.”Achin Gupta, on the call for July to September 2026

What management guided

• FY27 operating margin of 18.5%-20%, with sequential improvement expected in each remaining quarter.
• Generic Advair launch in Q3, with revenues building through Q3 and Q4.
• Three further significant US launches (two respiratory, one peptide) expected in FY27; 45-50 North American filings over 3 years and pembrolizumab filing next year.
• FY27 R&D expense of 6%-7% of revenue.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 27 October 2026.

When Cipla reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Ventolin supply ramp at the North American facility; check for stronger sales as manufacturing scales.

Cipla is on 2 of our India lists: Nifty 50 companies and Pharma stocks.

Cipla Ltd earned ₹852 Cr of net profit in the Sep 2026 quarter, −37.0% on the same quarter a year earlier. Full-year FY26 profit was ₹3,862 Cr. Over 10 years profit has grown 10.8% a year on average. That is 11.5% of the quarter's revenue. The same quarter a year earlier earned ₹1,353 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹3,862 Cr (−26.7% on the year before).

Why profit moved: revenue changed −2.4% on a year earlier and the margin moved −6.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −47.2% and revenue −0.7%. Profit is growing slower than sales: rising costs are taking part of the growth.

Cipla Ltd reported ₹7,404 Cr of revenue in the Sep 2026 quarter, −2.4% on the same quarter a year earlier. Over 10 years it has grown 7.4% a year on average. The last full year, FY26, came in at ₹28,163 Cr. The last four reported quarters add to ₹28,138 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹28,163 Cr, +2.2% on the year before.

Recent pace: the last four quarters grew −0.7% on average, against 7.4% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −0.7%, against +3.0% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −47.5%, against −20.2% a year (rolling over).

Cipla Ltd's operating margin was 19.0% in the Sep 2026 quarter, 6.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 17.0% and 26.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −6.2 percentage points on the year while gross margin changed −2.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 98% of Cipla Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹3,940 Cr of operating cash against ₹3,862 Cr of profit. After ₹4,115 Cr of spending on assets, free cash was −₹175 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 98% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building.

Cipla Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 202 days in FY26, up from 195 days in FY21. It spent ₹7,592 Cr on assets over the last 3 years. Customers take 73 days to pay, and stock sits for 252 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹28,163 Cr, each day of that cycle ties up about ₹77.2 Cr, so roughly ₹15,586 Cr is tied up in the business at any time.

FY26: customers took 73 days to pay and stock sat for 252 days, about 8.3 months of sales sitting as stock, for a full cycle of 202 days, longer than FY21's 195.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 252 days. Customers pay about 73 days after that. Suppliers are paid at 123 days. Together that makes the 202-day cycle.

Spending on assets: ₹7,592 Cr over the last 3 years, against ₹3,369 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹2,042 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Cipla Ltd's P/E is 36.5×, near the high end of its own history: higher than 80% of past readings. Its usual P/E (the middle reading) is 29.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹35.87.